Hilton, J. F., Ott, P. A., Hansen, A. R., Li, Z., Mathew, M., Messina, C. H., Dave, V., Ji, X., Karpinich, N. O., Hirschfeld, S., Ballas, M., & Zandberg, D. P. (2024). INDUCE-2: A Phase I/II, open-label, two-part study of feladilimab in combination with tremelimumab in patients with advanced solid tumors. Cancer Immunology, Immunotherapy, 73(3). https://doi.org/10.1007/s00262-023-03623-z
Subjects:
Head and Neck Neoplasms
(MeSH)
Cancer Immunotherapy
(OpenAlex Topic)
Chimeric Antigen Receptor T Cell Therapy
(OpenAlex Topic)
Immunobiology of Dendritic Cells
(OpenAlex Topic)
Publication Type:
Article
Unique ID:
10.1007/s00262-023-03623-z
PMID:
Journal:
Publication Date:
Data Source:
OpenAlex